Mirati Therapeutics (NASDAQ:MRTX) Research Coverage Started

StockNews.com assumed coverage on shares of Mirati Therapeutics (NASDAQ:MRTX – Free Report) in a research report report published on Friday morning. The brokerage issued a sell rating on the biotechnology company’s stock. MRTX has been the subject of a number of other reports. SVB Leerink reiterated a market perform rating and issued a $58.00 price […]

Related Keywords

Westchester , Ohio , United States , Leerink Partnrs , Jamie Christensen , Stifel Nicolaus , Benjamin Hickey , Securities Exchange Commission , Citigroup , Mirati Therapeutics Company Profile , Mirati Therapeutics Inc , Exome Asset Management , Westchester Capital Management , Mirati Therapeutics , Free Report , Exchange Commission , Avenue Partners , Employees Retirement System , Asset Management , Get Free Report , Mirati Therapeutics Daily , Nasdaq Mrtx , Mrtx , Medical , Initiated Coverage , Stocknews Com ,